Skip to content
value.today

Altimmune, Inc.

ALT
$459 Mmarket cap on Oct 16, 2026-26.9% since Jan 2024
1D
-2.9%
Compare
World rank
#12,938
Revenue
$0 M
For year ending December-2025
Net income
$-88 M
-220225.0% margin
SEC filing
Employees
55
As on June 2022
value.today research

Altimmune, Inc. in brief

Altimmune, Inc. is a listed company in the Biotechnology industry, based in Maryland, USA. It was founded in 1997. Its market value was $459 M on 16 October 2026, which makes it the 12,938th largest listed company in the world and the 2,582nd largest in the USA on this site. In the year to December 2025 it had sales of $0 M and a net loss of $88 M. It employs about 55 people and Jerome Benedict Durso is its chief executive. Its shares trade under the symbol ALT (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Altimmune, Inc.

Altimmune, Inc. is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases and intranasal vaccines. The company annual revenue is 8.1 million USD and total assets are 245 million USD as on 2020. The headquarters is in USA.

Altimmune, Inc. timeline

5 events, 1997–2018
  1. 1997
  2. 🏁
    · approximate
    Founded
  3. 2005
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2007
  6. ✎
    Renamed Pharmathene, Inc
    Formerly Healthcare Acquisition Corp.
  7. 2017
  8. ✎
    Renamed Altimmune, Inc.
    Formerly Pharmathene, Inc.
  9. 2018
  10. •
    Legal Entity Identifier issued
    LEI 549300EOYCQ8SW3NVE64 registered.

Events of Altimmune, Inc. from Wikidata, SEC EDGAR and the GLEIF LEI register. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$208 M$416 M$625 M$833 M2020202120222023202420252026

World rank over time

▲ up 10,877 places since 2020
2020-01-01: #23842#23,84220202021-01-01: #12671#12,67120212022-01-07: #15840#15,84020222022-12-25: #9786#9,78620222023-07-30: #19228#19,22820232024-01-05: #11223#11,22320242026-03-08: #7676#7,67620262026-08-01: #11718#11,71820262026-10-14: #12896#12,89620262026-10-16: #12965#12,9652026

Rank in USA: #4,355 (Jan 2020) · #2,993 (Jan 2021) · #3,336 (Jan 2022) · #2,220 (Dec 2022) · #3,800 (Jul 2023) · #2,361 (Jan 2024) · #1,360 (Mar 2026) · #2,451 (Aug 2026) · #2,560 (Oct 2026) · #2,585 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
11480.8×
Price / book
2.0×
Free cash flow yield
-14.7%
Net margin
-220225.0%
Operating margin
-236225.0%
Return on equity
-39.2%
Liabilities / assets
19.7%
Net debt
$-9M
Revenue growth
+100.0%
R&D / revenue
166075.0%
Revenue per employee
$1 K
Profit per employee
$-1.6 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $10M, net income $-39M$10MFY18Fiscal year ending Dec 2019: revenue $6M, net income $-21M$6MFY19Fiscal year ending Dec 2020: revenue $8M, net income $-49M$8MFY20Fiscal year ending Dec 2021: revenue $4M, net income $-97M$4MFY21Fiscal year ending Dec 2022: revenue —, net income $-85M—FY22Fiscal year ending Dec 2023: revenue $0M, net income $-88M$0MFY23Fiscal year ending Dec 2024: revenue $0M, net income $-95M$0MFY24Fiscal year ending Dec 2025: revenue $0M, net income $-88M$0MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$0M+100.0%$-94M$-88M-220225.0%
Dec 2024$0M-95.3%$-103M$-95M-475300.0%
Dec 2023$0M—$-96M$-88M-20569.8%
Dec 2022——$-88M$-85M—
Dec 2021$4M-46.2%$-97M$-97M-2201.6%
Dec 2020$8M+41.2%$-55M$-49M-598.8%
Dec 2019$6M-43.9%$-21M$-21M-353.8%
Dec 2018$10M—$-43M$-39M-379.2%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-68M$0M$-68M$-1.00—
Dec 2024$-80M——$-1.34—
Dec 2023$-76M$0M$-76M$-1.66—
Dec 2022$-63M$0M$-63M$-1.81—
Dec 2021$-78M$12M$-90M$-2.35—
Dec 2020$-34M$0M$-35M$-1.91—
Dec 2019$-10M$0M$-10M$-1.60—
Dec 2018$-9M$1M$-10M$-15.16—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $0M, net income $-23M$0MDec ’24Three months to Mar 2025: revenue $0M, net income $-20M$0MMar ’25Three months to Jun 2025: revenue $0M, net income $-22M$0MJun ’25Three months to Sep 2025: revenue $0M, net income $-19M$0MSep ’25Three months to Dec 2025 (from the annual report): revenue $0M, net income $-27M$0MDec ’25Three months to Mar 2026: revenue —, net income $-23M—Mar ’26Three months to Jun 2026: revenue —, net income $-23M—Jun ’26Three months to Sep 2026: revenue —, net income $-32M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-32M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Altimmune, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$0 M
Operating income
$-94 M
Net income
$-88 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$280 M
Total liabilities
$55 M
Total equity
$225 M

As of December-2025

Top 100 institutional investors in Altimmune, Inc.#

As of Sep 30, 2026
191 institutions held 142.4 M shares (about 73.2% of the shares outstanding) on Sep 30, 2026. The ten largest hold 47.4%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Altimmune, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1BlackRock, Inc.20,960,259+574,975 (+2.82%)10.77%$60 MNov 13, 2026
2Deep Track Capital, LP19,250,0000 (0.00%)9.89%$55 MNov 16, 2026
3State Street Corp8,356,408-3,742,132 (-30.93%)4.29%$24 MNov 12, 2026
4Vanguard Portfolio Management LLC8,107,554+777,289 (+10.60%)4.17%$23 MNov 13, 2026
5Vanguard Capital Management LLC7,812,919-364,833 (-4.46%)4.02%$22 MNov 13, 2026
6Viking Global Investors LP6,700,0000 (0.00%)3.44%$19 MNov 16, 2026
7Ra Capital Management, L.P.6,500,0000 (0.00%)3.34%$19 MNov 16, 2026
8Marshall Wace, LLP5,431,302-1,409,753 (-20.61%)2.79%$16 MNov 13, 2026
9Geode Capital Management, LLC4,884,491-126,823 (-2.53%)2.51%$14 MNov 6, 2026
10Two Sigma Investments, LP4,241,069+1,859,927 (+78.11%)2.18%$12 MNov 16, 2026
11Trails Edge Capital Partners, LP4,230,000+1,570,000 (+59.02%)2.17%$12 MNov 16, 2026
12Millennium Management LLC3,844,940+535,818 (+16.19%)1.98%$11 MNov 16, 2026
13Woodline Partners LP3,400,3120 (0.00%)1.75%$10 MNov 16, 2026
14Goldman Sachs Group Inc2,479,456+265,006 (+11.97%)1.27%$7 MNov 16, 2026
15Nuveen, LLC2,147,105-258,249 (-10.74%)1.10%$6 MNov 10, 2026
16Weiss Asset Management LP2,029,320+498,517 (+32.57%)1.04%$6 MNov 16, 2026
17Great Point Partners LLC1,741,2320 (0.00%)0.89%$5 MNov 16, 2026
18Nantahala Capital Management, LLC1,720,000-1,280,000 (-42.67%)0.88%$5 MNov 13, 2026
19FMR LLC1,612,459+863,485 (+115.29%)0.83%$5 MNov 10, 2026
20Point72 Asset Management, L.P.1,458,907+972,023 (+199.64%)0.75%$4 MNov 16, 2026
21Northern Trust Corp1,458,532-140,694 (-8.80%)0.75%$4 MNov 16, 2026
22Susquehanna International Group, LLP1,423,141+692,063 (+94.66%)0.73%$4 MNov 16, 2026
23Bank Of America Corp /de/1,292,126+534,207 (+70.48%)0.66%$4 MNov 16, 2026
24Vanguard Fiduciary Trust Co1,122,754-170,247 (-13.17%)0.58%$3 MNov 13, 2026
25UBS Group AG951,139+84,754 (+9.78%)0.49%$3 MNov 10, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Altimmune, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Barclays PLC922,127+570,540 (+162.28%)0.47%$3 MNov 6, 2026
27Morgan Stanley850,208+91,773 (+12.10%)0.44%$2 MNov 13, 2026
28Ghisallo Capital Management LLC750,0000 (0.00%)0.39%$2 MNov 16, 2026
29Hennion & Walsh Asset Management, Inc.744,997+226,799 (+43.77%)0.38%$2 MOct 13, 2026
30Squarepoint Ops LLC740,634+538,254 (+265.96%)0.38%$2 MNov 9, 2026
31Citadel Advisors LLC693,769-289,790 (-29.46%)0.36%$2 MNov 16, 2026
32Bank of New York Mellon Corp670,825-18,888 (-2.74%)0.34%$2 MNov 5, 2026
33Tang Capital Management LLC666,0220 (0.00%)0.34%$2 MNov 16, 2026
34Wellington Management Group LLP663,764+243,464 (+57.93%)0.34%$2 MNov 16, 2026
35Dimensional Fund Advisors LP626,553-12,883 (-2.01%)0.32%$2 MNov 4, 2026
36Charles Schwab Investment Management Inc607,885-16,614 (-2.66%)0.31%$2 MNov 16, 2026
37D. E. Shaw & Co., Inc.573,943+372,305 (+184.64%)0.29%$2 MNov 16, 2026
38BNP Paribas Financial Markets460,111+88,935 (+23.96%)0.24%$1 MNov 12, 2026
39Beirne Wealth Consulting Services, LLC421,8580 (0.00%)0.22%$1 MOct 19, 2026
40Balyasny Asset Management L.P.402,500New0.21%$1 MNov 16, 2026
41HSBC Holdings PLC378,840+314,380 (+487.71%)0.19%$1 MNov 16, 2026
42Invesco Ltd.343,802+11,210 (+3.37%)0.18%$1 MNov 12, 2026
43HRT Financial LP339,221New0.17%$1 MNov 13, 2026
44Elo Mutual Pension Insurance Co328,217New0.17%$1 MNov 12, 2026
45Rhumbline Advisers320,348+10,742 (+3.47%)0.16%$1 MNov 10, 2026
46Janney Montgomery Scott LLC312,710+10,100 (+3.34%)0.16%$1 MNov 12, 2026
47LMR Partners LLP300,0000 (0.00%)0.15%$1 MNov 16, 2026
48Steward Partners Investment Advisory, LLC267,884+1,213 (+0.45%)0.14%$1 MNov 13, 2026
49Alps Advisors Inc255,875+58,501 (+29.64%)0.13%$1 MNov 3, 2026
50Brown Wealth Management, LLC240,136+4,000 (+1.69%)0.12%$1 MOct 20, 2026
51Baird Financial Group, Inc.237,5220 (0.00%)0.12%$1 MNov 13, 2026
52Stifel Financial Corp212,106+19,738 (+10.26%)0.11%$1 MNov 12, 2026
53Commonwealth Equity Services, LLC210,431-4,143 (-1.93%)0.11%$1 MNov 2, 2026
54Rafferty Asset Management, LLC193,186-31,874 (-14.16%)0.10%$1 MNov 13, 2026
55Deutsche Bank AG\169,612-25,402 (-13.03%)0.09%$0 MNov 6, 2026
56Creative Planning161,008-57,273 (-26.24%)0.08%$0 MNov 2, 2026
57Birchview Capital, LP160,964+8,283 (+5.43%)0.08%$0 MNov 13, 2026
58ExodusPoint Capital Management, LP160,762New0.08%$0 MNov 16, 2026
59Price T Rowe Associates Inc /MD/158,259-7,131 (-4.31%)0.08%$0 MNov 16, 2026
60Prudential Financial Inc156,796+121,606 (+345.57%)0.08%$0 MNov 16, 2026
61Simplex Trading, LLC146,416New0.08%$0 MNov 4, 2026
62Citigroup Inc140,846-153,102 (-52.08%)0.07%$0 MNov 4, 2026
63LPL Financial LLC126,865+4,913 (+4.03%)0.07%$0 MNov 6, 2026
64Wealth Effects LLC125,950+3,300 (+2.69%)0.06%$0 MOct 23, 2026
65Gsa Capital Partners LLP124,380New0.06%$0 MNov 16, 2026
66Man Group plc124,093-49,779 (-28.63%)0.06%$0 MNov 16, 2026
67Voleon Capital Management LP121,729+101,014 (+487.64%)0.06%$0 MNov 16, 2026
68Virtus Investment Advisers, LLC121,584-3,779 (-3.01%)0.06%$0 MNov 12, 2026
69Susquehanna Portfolio Strategies, LLC120,554+17,180 (+16.62%)0.06%$0 MNov 16, 2026
70Jpmorgan Chase & Co113,791+7,166 (+6.72%)0.06%$0 MNov 12, 2026
71Renaissance Technologies LLC108,146+36,546 (+51.04%)0.06%$0 MNov 12, 2026
72Alliancebernstein L.P.107,490-33,360 (-23.68%)0.06%$0 MNov 16, 2026
73MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.106,947-10,735 (-9.12%)0.06%$0 MNov 16, 2026
74Silvercrest Asset Management Group LLC103,5000 (0.00%)0.05%$0 MNov 16, 2026
75Summit Financial Wealth Advisors, LLC103,2880 (0.00%)0.05%$0 MOct 15, 2026
76ADAR1 Capital Management, LLC102,8230 (0.00%)0.05%$0 MNov 16, 2026
77MetLife Investment Management, LLC102,616-14,240 (-12.19%)0.05%$0 MNov 16, 2026
78Nomura Asset Management International Inc.100,0000 (0.00%)0.05%$0 MNov 16, 2026
79Leonteq Securities AG100,000+36,000 (+56.25%)0.05%$0 MOct 29, 2026
80Wells Fargo & Company/mn87,818-129,612 (-59.61%)0.05%$0 MNov 16, 2026
81Canada Pension Plan Investment Board87,3000 (0.00%)0.04%$0 MNov 16, 2026
82WINTON GROUP Ltd86,900+70,800 (+439.75%)0.04%$0 MNov 12, 2026
83Corient Private Wealth LP85,400+31,174 (+57.49%)0.04%$0 MNov 16, 2026
84Brevan Howard Capital Management LP82,229-48,552 (-37.12%)0.04%$0 MNov 16, 2026
85Jump Financial, LLC81,441-108,559 (-57.14%)0.04%$0 MNov 13, 2026
86Profund Advisors LLC69,238-44,360 (-39.05%)0.04%$0 MOct 29, 2026
87Ameriprise Financial Inc68,719+148 (+0.22%)0.04%$0 MNov 16, 2026
88Vanguard Global Advisers, LLC65,204-9,841 (-13.11%)0.03%$0 MNov 13, 2026
89AQR Capital Management LLC63,485-1,157,464 (-94.80%)0.03%$0 MNov 16, 2026
90Graham Capital Management, L.P.62,614+17,674 (+39.33%)0.03%$0 MNov 16, 2026
91Police & Firemen's Retirement System of New Jersey58,6250 (0.00%)0.03%$0 MNov 9, 2026
92New York State Common Retirement Fund52,7470 (0.00%)0.03%$0 MNov 17, 2026
93Cetera Investment Advisers51,675-226 (-0.44%)0.03%$0 MNov 13, 2026
94Rockefeller Capital Management L.P.50,115+375 (+0.75%)0.03%$0 MNov 13, 2026
95Manufacturers Life Insurance Company, The49,299-2,737 (-5.26%)0.03%$0 MNov 13, 2026
96Russell Investments Group, Ltd.44,066+370 (+0.85%)0.02%$0 MNov 6, 2026
97Tower Research Capital LLC (TRC)41,101+33,624 (+449.70%)0.02%$0 MNov 16, 2026
98Voya Investment Management LLC38,625-1,158 (-2.91%)0.02%$0 MNov 10, 2026
99MML Investors Services, LLC36,719+2,169 (+6.28%)0.02%$0 MNov 13, 2026
100Osaic Holdings, Inc.35,678+14,600 (+69.27%)0.02%$0 MNov 12, 2026

All 191 institutional investors, with who bought and sold →

Superinvestors holding Altimmune, Inc.

1 of the well-known investors value.today follows, from their newest Form 13F.

Mutual funds holding Altimmune, Inc.#

112 funds hold shares worth $130 M (about 22.2% of the company). Since their previous reports 76 added shares and 19 sold, buying $40 M net.
Mutual funds holding Altimmune, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 State Street SPDR S&P Biotech ETFSSGA Funds Management, Inc.8.10 M$25 M4.2%0.23%+86%Jun 30, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.5.75 M$17 M3.0%<0.01%+40%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors5.16 M$16 M2.7%0.02%+64%Jun 30, 2026
🇺🇸 Vanguard Strategic Equity FundThe Vanguard Group, Inc.2.52 M$8 M1.3%0.06%+37%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.2.24 M$7 M1.1%<0.01%+58%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC2.17 M$6 M1.1%0.02%+68%Jul 31, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors1.87 M$6 M0.96%0.04%newJun 30, 2026
🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors1.30 M$4 M0.67%0.04%+40%Jun 30, 2026
🇺🇸 Vanguard Explorer FundThe Vanguard Group, Inc.1.21 M$3 M0.62%0.02%no changeJul 31, 2026
🇺🇸 BlackRock Advantage Small Cap Core FundBlackRock Advisors, LLC1.05 M$3 M0.54%0.06%+74%May 29, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC988,478$3 M0.51%<0.01%+79%May 31, 2026
🇺🇸 Vanguard Strategic Small-Cap Equity FundThe Vanguard Group, Inc.867,177$3 M0.45%0.08%+38%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.670,084$2 M0.34%0.01%+53%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors668,001$2 M0.34%0.13%+103%Jun 30, 2026
🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC638,025$2 M0.33%0.03%+11%Jun 30, 2026
🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc.567,179$2 M0.29%<0.01%+114%May 31, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.483,547$1 M0.25%0.02%+69%Jul 31, 2026
🇺🇸 Vanguard Market Neutral FundThe Vanguard Group, Inc.400,755$1 M0.21%0.20%+17%Jun 30, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC371,571$1 M0.19%0.02%+75%Jun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC357,417$1 M0.18%<0.01%+79%May 31, 2026
🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors355,966$1 M0.18%<0.01%+81%Jun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC290,374$1 M0.15%<0.01%+92%May 31, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC277,849$1 M0.14%0.04%newJun 30, 2026
🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc.276,644$1 M0.14%0.05%no changeJun 30, 2026
🇺🇸 Direxion Daily S&P Biotech Bull 3X SharesRAFFERTY ASSET MANAGEMENT, LLC275,123$1 M0.14%0.16%+11%Jul 31, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC264,710$1 M0.14%0.02%+70%Jul 31, 2026
🇺🇸 BlackRock Advantage Small Cap Growth FundBlackRock Funds233,173$1 M0.12%0.09%+29%Jun 30, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC216,279$1 M0.11%0.02%+63%Jun 30, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP210,694$1 M0.11%<0.01%−5.7%Jul 31, 2026
🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC183,869$1 M0.09%0.02%+8.2%Jul 31, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP167,692$0 M0.09%<0.01%−60%Jul 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation142,900$0 M0.07%0.02%+171%Jun 30, 2026
🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC141,468$0 M0.07%<0.01%no changeJun 30, 2026
🇺🇸 ALPS Medical Breakthroughs ETFALPS Advisors, Inc.134,076$0 M0.07%0.25%+44%May 31, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.140,831$0 M0.07%<0.01%+117%Jul 31, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.121,751$0 M0.06%0.02%+50%May 31, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC113,443$0 M0.06%<0.01%+59%Jul 31, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.102,890$0 M0.05%0.02%+61%Jun 30, 2026
🇺🇸 Nomura Healthcare FundDelaware Management Company100,000$0 M0.05%0.04%no changeJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.99,551$0 M0.05%<0.01%+30%Jun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.94,001$0 M0.05%<0.01%+63%Jun 30, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC99,727$0 M0.05%<0.01%no changeJul 31, 2026
🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC90,074$0 M0.05%0.04%no changeJun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC94,969$0 M0.05%0.02%+68%Jul 31, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC80,290$0 M0.04%0.01%+85%Jun 30, 2026
🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors77,572$0 M0.04%<0.01%+9.9%Jun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC74,612$0 M0.04%<0.01%+14%May 31, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC72,116$0 M0.04%<0.01%+66%Jul 31, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC66,249$0 M0.03%0.02%+58%Jun 30, 2026
🇺🇸 Biotechnology Ultrasector ProfundProFund Advisors LLC77,039$0 M0.04%0.11%—Apr 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC60,560$0 M0.03%<0.01%+157%Jun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC57,050$0 M0.03%0.02%+69%Jun 30, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company53,983$0 M0.03%0.01%+57%May 31, 2026
🇺🇸 BlackRock Advantage SMID Cap Fund, Inc.BlackRock Advisors, LLC54,155$0 M0.03%0.02%no changeJun 30, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.51,100$0 M0.03%<0.01%+15%Jun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC44,584$0 M0.02%0.06%+91%Jun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC44,183$0 M0.02%0.01%+40%Jun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS43,844$0 M0.02%0.02%+71%Jun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC40,851$0 M0.02%0.02%+72%Jun 30, 2026
🇺🇸 Strategic Advisers U.S. Total Stock FundStrategic Advisers LLC36,028$0 M0.02%<0.01%no changeMay 31, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC38,622$0 M0.02%<0.01%+55%Jul 31, 2026
🇺🇸 GMO U.S. Equity FundGrantham, Mayo, Van Otterloo & Co. LLC35,659$0 M0.02%0.05%−43%May 31, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP34,439$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.31,195$0 M0.02%0.02%+72%Jun 30, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC31,031$0 M0.02%0.02%newJun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.30,317$0 M0.02%0.02%+103%Jun 30, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC30,070$0 M0.02%0.02%+55%Jul 31, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC26,807$0 M0.01%0.02%+73%Jun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC24,605$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 Dimensional U.S. Equity Market ETFDimensional Fund Advisors LP25,408$0 M0.01%<0.01%no changeJul 31, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC23,594$0 M0.01%0.02%+78%Jun 30, 2026
🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors22,987$0 M0.01%<0.01%−0.8%Jun 30, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC23,277$0 M0.01%0.02%+131%Jul 31, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.21,218$0 M0.01%<0.01%+44%Jul 31, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management18,039$0 M<0.01%0.02%+69%Jun 30, 2026
🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC17,801$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC17,574$0 M<0.01%0.04%newJun 30, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS17,598$0 M<0.01%0.02%+74%Jul 31, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC15,867$0 M<0.01%0.02%+62%Jun 30, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC13,643$0 M<0.01%0.02%+76%Jun 30, 2026
🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC13,155$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION11,800$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.11,582$0 M<0.01%<0.01%+47%May 31, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC10,948$0 M<0.01%<0.01%+64%Jun 30, 2026
🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC9,946$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 BlackRock Advantage SMID Cap V.I. FundBlackRock Advisors, LLC9,834$0 M<0.01%0.02%no changeJun 30, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC9,800$0 M<0.01%<0.01%+20%Jun 30, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.9,521$0 M<0.01%<0.01%+2114%Jun 30, 2026
🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP9,653$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC8,939$0 M<0.01%<0.01%−1.7%Jun 30, 2026
🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc.7,696$0 M<0.01%<0.01%−4.1%Jun 30, 2026
🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP8,167$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC6,983$0 M<0.01%<0.01%+76%Jun 30, 2026
🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS6,838$0 M<0.01%<0.01%+418%Jul 31, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC6,144$0 M<0.01%<0.01%+60%May 31, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.5,018$0 M<0.01%<0.01%+126%Jun 30, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC4,861$0 M<0.01%<0.01%−11%May 31, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC4,804$0 M<0.01%<0.01%−12%May 31, 2026
🇺🇸 AZL DFA U.S. Core Equity FundAllianz Investment Management LLC4,823$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 SA U.S. Small Company FundFocus Advisor Solutions, LLC4,035$0 M<0.01%<0.01%no changeJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Altimmune, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$467 K
15 purchases, 7 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$467 K
open market only
Insiders on file
48
since
$110 K-$111 K$0Aug 2024: bought $0 (0 trades), sold $111 K (2 trades)Aug 24Mar 2025: bought $58 K (2 trades), sold $0 (0 trades)MarDec 2025: bought $105 K (3 trades), sold $0 (0 trades)DecJan 2026: bought $23 K (2 trades), sold $0 (0 trades)Jan 26Mar 2026: bought $89 K (2 trades), sold $0 (0 trades)MarApr 2026: bought $110 K (3 trades), sold $0 (0 trades)AprAug 2026: bought $44 K (1 trades), sold $0 (0 trades)AugNov 2026: bought $96 K (4 trades), sold $0 (0 trades)Nov
Bought (open market)Sold (open market)Hover a month for the totals
Altimmune, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Richard Thomas MenziusoPrincipal Accounting OfficerBuy+10,000$1.419$14 K10,000Form 4
filed Gregory L. WeaverChief Financial OfficerBuy+10,000$1.620$16 K73,005Form 4
filed Jerome Benedict DursoPresident and CEO, DirectorBuy+30,700$1.619$50 K93,200Form 4
filed Wayne PisanoDirectorBuy+10,000$1.635$16 K58,800Form 4
filed Gregory L. WeaverChief Financial OfficerOption exercise+18,750——68,677Form 4
filed Gregory L. WeaverChief Financial OfficerShares withheld for tax-5,672$1.930$11 K63,005Form 4
filed Christophe Arbet-EngelsChief Medical OfficerOption exercise+37,500——37,500Form 4
filed Gregory L. WeaverChief Financial OfficerOption exercise+14,475——54,306Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Altimmune, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
42.1 M
38.0% of shares · 12.16 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-33.33 reverse split

Fails to deliver

  • : 11,386 shares at $2.36
  • : 631 shares at $2.43
  • : 2,146 shares at $2.86
  • : 3,623 shares at $3.06
  • : 1,957 shares at $3.41

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Altimmune, Inc. scorecard#

Passes 4 of the 15 checks that could be worked out: strongest in financial health (3 of 5), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 16, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median2.0×Price to book 2.0× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-14.7%Free cash flow is -14.7% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-1.00 vs -1.34Diluted EPS -1.00 in fiscal 2025 against -1.34 the year before (report's currency).
    • ✗Net income higher than five years earlier-$88 M-$88 M in fiscal 2025 against -$49 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$88 MNet income -$88 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-50.6%-50.6% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health3 of 5
    • ✓Short-term assets cover short-term liabilities18.6×Current ratio 18.55 at the end of fiscal 2025.
    • ✓Debt below equity0.1×Debt to equity 0.15 at the end of fiscal 2025.
    • ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $9 M at the end of fiscal 2025.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone1.77Z-score 1.77 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year24.1%Diluted shares up 24.1% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Altimmune, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Altimmune, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue0.00.00.4−0.14.4r8.25.810113.2
Research and development6682667175r501818187.2r
General and administrative2821181715r138.59.88.57.1r
Operating expenses951039688101r6327536314r
Operating income−94−103−96−88−97r−55−21−43−52−11r
Interest and finance income7.58.17.42.90.2r0.30.80.20.00.0
Interest expense and finance costs1.60.00.00.00.0r0.00.00.30.20.0
Net interest income—————————0.2
Other non-operating income (expense)5.78.17.52.8−0.2r0.30.9−2.5−0.00.0r
Income before tax−89−95−88−85−97r−54−21−45−52−11r
Income tax−0.7——−0.2—−5.4−0.1−6.1−5.60r
Net income including minority interests−88−95−88−85−97r−49−21−39−46—
Net income attributable to shareholders−88−95−88−85−97r−49−21−39−46−11r
Earnings per share, basic-1.00-1.34-1.66-1.81-2.35-1.91-1.60-15.16-118.91r2.97
Earnings per share, diluted-1.00-1.34-1.66-1.81-2.35-1.91-1.60-15.16-118.91r2.95
Shares, weighted average (basic)887153474126———65
Shares, weighted average (diluted)887153474126132.80.4r66
Balance sheet
Cash and cash equivalents4437135111190r1169.0348.82.9r
Short-term investments230956374—10028——67
Other current assets3.02.26.95.48.0r1.90.50.51.00.4r
Current assets278137210193204r2303939234.5r
Property, plant and equipment0.30.40.71.11.4r1.11.11.30.60.2r
Right-of-use (leased) assets1.41.60.40.60.8r0.90.7———
Goodwill——————00—19r
Other intangible assets—001212r1313143915
Total assets280139211207219r24554556338r
Accounts payable2.70.22.14.82.0r0.60.00.40.12.0r
Current liabilities1510121718r123.94.53.85.5r
Long-term debt34——4.61.5r1.81.91.9——
Lease liabilities (non-current)1.11.40.20.71.1r1.51.5———
Non-current liabilities—5.34.44.6——————
Total liabilities5516172220r198.56.4146.2r
Retained earnings−649−561−466−378−293r−186−137−117−78−31r
Shareholders' equity225124194185199r226r46483932r
Total liabilities and equity280139211207219r24554556338r
Shares outstanding1117271494137159.10.6r6.9r
Cash-flow statement
Depreciation and amortization———−0.20.60.4r0.4———
Share-based compensation1614118.15.5r2.61.30.81.41.0r
Cash from operating activities−68−80−76−63−78r−34r−9.6−9.4−20−6.4r
Capital expenditure−0.0—−0.0−0.1−12r−0.2−0.0−1.0−0.1−0.1r
Intangible assets bought————−0.2r−0.1−0.0−0.0−0.1−0.1
Cash from investing activities−132−2814−7388r−72r−28−1.014−0.2r
Debt issued35————————0.0
Shares issued17410.0875665r48—4.3—3.8
Cash from financing activities20710865765r2131332165.0r
Exchange-rate effect on cash———————−0.10.1−0.2r
Change in cash6.8−9824−7974r107−25229.4138
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Where Altimmune, Inc. operates: 3 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 4 subsidiaries on file.

Altimmune, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters2 offices2 subsidiaries—
🇦🇺 Australia1 subsidiary—
🇬🇧 UK1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at Altimmune, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$8.0 M
Vipin Garg
Other top executives, average
$2.4 M
the CEO earned 3.4× this
$100 invested is now
$22
Altimmune, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Vipin Garg$8.0 M$1.8 M$2.4 M$22
2024Jerome Benedict Durso$6.1 M$2.5 M$2.4 M$79
2023Jerome Benedict Durso$5.5 M$2.1 M$2.6 M$123

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Altimmune, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 7 · Material agreement 5 · Agreement ended 1 · New debt 3 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 9

Altimmune, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
New debt8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Bylaws or fiscal year changedShareholder vote8-K
Results announced8-K
Material agreement8-K
Directors and officers8-K
Material agreementNew debtResults announced8-K
Material agreementAgreement ended8-K
Directors and officers8-K
Shareholder vote8-K
Results announced8-K
Material agreementNew debtResults announced8-K
Directors and officersResults announced8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Shareholder vote8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

2 private funding rounds before listing

Private share sales · funding history

Private share sales of Altimmune, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2010$10 MNo. 2$2 to $10 million22equitySEC
Jul 2009$19 MNo. 1$10 to $50 million22debt, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Altimmune, Inc.#

$0 spent on lobbying the US Congress and federal agencies in 2022.

Lobbying, 2022
$0
#1,458 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2022
2026 so far
—

Lobbying firms hired in 2022

BGR Government Affairs

Altimmune, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2022$0—1
2021$250 K—6
2020$315 K—7

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Altimmune, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

H-1B hiring at Altimmune, Inc.#

1 labor condition applications certified in fiscal 2020 for 1 positions, at a median wage of $127 K a year.

Certified, FY2020
1
#1,882 among companies on value.today
Worker positions
1
Median wage offered
$127 K
a year, full-time
Applications filed
1
Altimmune, Inc.: most frequent H-1B job titles in fiscal 2020
Job titlePositionsMedian wage offered
Senior BiostatisticianBiostatisticians1$127 K

Where: Gaithersburg, MD 1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Altimmune, Inc.

Discuss Altimmune, Inc.#

2 automatic updates and 0 member comments. Sign in to comment and react.

  • Results announced on 12 November 2026automatic update · Nov 12, 2026

    Altimmune, Inc. announced results on 12 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: a net loss of $32 million.

  • Mutual funds: 112 funds hold $130 millionautomatic update · Jul 31, 2026

    112 mutual funds in 1 country hold shares of Altimmune, Inc. worth $130 million, about 22.2% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 76 funds added shares and 19 sold; on balance they bought $40 million. Share splits are not counted as trading.

How Altimmune, Inc. compares in Biotechnology

  • Market cap$459 M · higher than 57% of 726
  • Revenue$0 M · higher than 14% of 647
  • Revenue growth100.0% · higher than 82% of 438
  • Price / book2.0× · lower than 58% of 534
  • FCF yield-14.7% · higher than 50% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Altimmune, Inc.🇺🇸$459 M——+100.0%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 16, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As on June 2022
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Altimmune, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Altimmune, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Altimmune, Inc.? Suggest a correction